Innovators can exit with an idea How to Monetizing Patents and ideas: yazamIP.com launches Idea Lab
Reporter: Aviva Lev-Ari, PhD, RN
1. yazamIP.com launches Idea Lab, enabling innovators to exit without necessarily establishing a startup.
If you: (A) have a track record of innovation and have a solution for a significant technical problem, and (B) are interested in either of the options below, both have no cost to you: (i) a $1,000,000 “exit” from your idea without necessarily leaving your “day-job”; (ii) having proven innovation, patent and business experts work with you to establish a robust patent portfolio based on your idea. And you maintain the option to spin off the strong portfolio into a startup for you to build the market.
Then yazamIP.com’s Idea Lab is for you. See http://www.yazamip.com/valuations
2. Tel Aviv University’s Ramot raises $17m from Tata & SanDisk.http://yazamip.com/node/84
3. Elvis Presley IP sells. http://yazamip.com/node/82
4. Innovation and patents are helping to increase gun sales.http://yazamip.com/node/85
Want to get a valuation on your patent? See http://yazamip.com/valuations
Do not forget to contact yazamIP.com to inquire about our most generous “referral a patent” fee arrangement.
3. Twitter has only 9 patents pre-IPO, a fact that has investors worried.http://www.yazamip.com/node/73
4. Marijuana-related patents? Now that is a market to corner!http://www.yazamip.com/node/77
- If the companies are in distress and have US patents then we can sell them for the inventor
- If the patents are being infringed upon, we can see how we can help the inventor get compensated
- If the inventors have great ideas that they have not turned into companies yet, we would consider investing in them to convert the ideas into patent portfolios
Reply to
“Monte Silver, yazamip.com, Idea Lab” <info@yazamip.com>
SOURCE
From: “Monte Silver, yazamip.com, Idea Lab via LinkedIn” <member@linkedin.com>
Reply-To: “Monte Silver, yazamip.com, Idea Lab” <info@yazamip.com>
Date: Sun, 8 Dec 2013 13:51:06 +0000 (UTC)
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: yazamIP.com launches Idea Lab. Innovators can exit with an idea
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.